Halozyme Therapeutics (DE:RV7)

Halozyme (RV7) Financial Statements


Halozyme Financial Overview

Halozyme's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Halozyme is scheduled to report earnings on August 6, 2024, and the estimated EPS forecast is €0.71. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 230.04M$ 216.03M$ 221.04M$ 162.14M$ 181.50M
Gross Profit$ 177.74M$ 161.21M$ 170.97M$ 126.97M$ 139.38M
EBIT$ 106.39M$ 106.27M$ 97.65M$ 56.78M$ 75.36M
EBITDA$ 127.09M$ 129.74M$ 118.68M$ 78.13M$ 79.91M
Net Income Common Stockholders$ 85.39M$ 68.64M$ 74.75M$ 39.62M$ 57.70M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 336.00M$ 483.28M$ 348.27M$ 275.61M$ 362.79M
Total Assets$ 1.73B$ 1.89B$ 1.81B$ 1.70B$ 1.84B
Total Debt$ 1.50B$ 1.50B$ 1.50B$ 1.49B$ 1.51B
Net Debt$ 1.16B$ 1.01B$ 1.15B$ 1.22B$ 1.14B
Total Liabilities$ 1.65B$ 1.64B$ 1.66B$ 1.63B$ 1.67B
Stockholders Equity$ 83.81M$ 249.18M$ 151.03M$ 65.85M$ 169.80M
Cash Flow-
Free Cash Flow$ 99.76M$ 129.47M$ 68.47M$ 75.56M$ 90.09M
Operating Cash Flow$ 102.35M$ 132.41M$ 66.85M$ 86.94M$ 82.45M
Investing Cash Flow$ -8.29M$ -83.45M$ 54.99M$ -60.16M$ -1.75M
Financing Cash Flow$ -249.92M$ 4.10M$ 2.45M$ -164.61M$ 6.33M
Currency in USD

Halozyme Earnings and Revenue History

Halozyme Debt to Assets

Halozyme Cash Flow

Halozyme Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis